Physician profile
Eric D Kramer
NPI 1801866587
$8,642.46
in general payments reported to CMS, 2019-2025
41 companies · $2,582 in 2025
The $2,582 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $212 · 2021: $1,081 · 2022: $894 · 2023: $1,299 · 2024: $2,575 · 2025: $2,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,455.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,335.56 | 2021-2025 | |
| Ucb, INC. | $1,080.15 | 2020-2025 | Briviact, Nayzilam, Zilbrysq |
| Mdd US Operations, LLC | $696.58 | 2022-2025 | Apokyn, Apokyn |
| Eisai INC. | $540.83 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $354.27 | 2020-2025 | Ingrezza, Ongentys |
| Biohaven Pharmaceuticals, INC. | $321.47 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $306.20 | 2024-2025 | Hyqvia |
| Lilly USA, LLC | $297.84 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Novartis Pharmaceuticals Corporation | $254.36 | 2020-2025 | |
| Pfizer INC. | $223.75 | 2024-2025 | |
| Sk Life Science, INC. | $220.88 | 2020-2024 | |
| Otsuka America Pharmaceutical, INC. | $217.97 | 2023-2025 | Rexulti, Nuedexta |
| Biohaven Pharmaceutical Holding Company Ltd. | $206.89 | 2022 | |
| Argenx US, INC. | $191.27 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $179.90 | 2023-2025 | Valtoco |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $160.23 | 2023-2025 | Vyepti, Rexulti |
| Kyowa Kirin, INC. | $139.58 | 2021-2025 | Nourianz |
| Biogen, INC. | $131.19 | 2020-2025 | Leqembi, Skyclarys |
| Amgen INC. | $94.95 | 2021-2023 | Aimovig |
| Allergan, INC. | $88.25 | 2020-2022 | |
| Merz Pharmaceuticals, LLC | $60.99 | 2024-2025 | Inbrija, Xeomin |
| Alexion Pharmaceuticals, INC. | $60.15 | 2021-2024 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $57.84 | 2023-2024 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $57.21 | 2020-2021 | |
| Avion Pharmaceuticals | $46.96 | 2022-2023 | Dhivy |
| Octapharma USA, INC. | $40.73 | 2022-2023 | Panzyga |
| Acadia Pharmaceuticals INC | $30.98 | 2020-2021 | |
| Boston Scientific Corporation | $29.69 | 2025 | Watchman Flx |
| Microtransponder, INC. | $24.65 | 2025 | |
| Vanda Pharmaceuticals INC. | $23.00 | 2025 | Ponvory |
| Medtronic, INC. | $21.83 | 2022 | |
| Greenwich Biosciences, INC. | $16.64 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.32 | 2025 | Keveyis |
| Alnylam Pharmaceuticals INC. | $15.92 | 2024 | Onpattro |
| Celgene Corporation | $15.43 | 2025 | Zeposia |
| Sobi, INC | $14.62 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.41 | 2025 | Crexont |
| Livanova USA, INC. | $14.15 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Hyperfine Operations, INC. | $13.87 | 2024 | Swoop |
| Emd Serono, INC. | $12.52 | 2021 | |
| Acorda Therapeutics, INC | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.